Arcellx, Inc.

ACLX · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
73
SEC Filings

Business Summary

PART I . Overview We are a clinical-stage biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases. We believe immunotherapies are one of the forward pillars of medicine, and our mission is to advance humanity by engineering immunotherapies that are safer, more effective and more broadly accessible. Although Chimeric Antigen Receptor T-cells (CAR-Ts) have shown benefits to date, they have primarily been constraine...

Next Earnings

Q2 FY2026 — expected 2026-08-07

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionACLXdiscussed_in_filing Cybersecurity
topic_mentionACLXdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-262025-12-310001193125-26-076876EDGAR116K words
2025-02-272024-12-310000950170-25-029150EDGAR—
2024-02-282023-12-310000950170-24-022048EDGAR—
2023-03-292022-12-310000950170-23-010610EDGAR—
2022-03-242021-12-310000950170-22-004573EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-052025-09-300001193125-25-266932EDGAR63K words
2025-08-072025-06-300000950170-25-105064EDGAR—
2025-05-082025-03-310000950170-25-067100EDGAR—
2024-11-072024-09-300000950170-24-123442EDGAR—
2024-08-082024-06-300000950170-24-094120EDGAR—
2024-05-092024-03-310000950170-24-057007EDGAR—
2023-11-132023-09-300000950170-23-062930EDGAR—
2023-08-142023-06-300000950170-23-042402EDGAR—
2023-05-082023-03-310000950170-23-018782EDGAR—
2022-11-142022-09-300000950170-22-025099EDGAR—
2022-08-152022-06-300000950170-22-017455EDGAR—
2022-05-122022-03-310000950170-22-009732EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-230001193125-26-063955EDGAR52K words
2025-12-080001193125-25-311276EDGAR—
2025-11-050001193125-25-266866EDGAR—
2025-08-070000950170-25-105015EDGAR—
2025-05-280001193125-25-129522EDGAR—
2025-05-140001193125-25-119506EDGAR—
2025-05-080001193125-25-116023EDGAR—
2025-03-200001193125-25-058978EDGAR—
2025-02-270001193125-25-039316EDGAR—
2024-12-120001193125-24-275844EDGAR—

73 total filings indexed. 46 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001786205
TickerACLX
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 4c717b305f8c19f72ff83c757e1b7ed0cc476e416fee4c0a6742773d8e74cbe3
parent: 43f5bc9a3d9a60bf02f8f19c8564e5501c6690aa8aee8e1fc38fb7e07491cda3
content hash: 43bef1cdfe20605ee22afbb3c83219d8c539090857d970454704315046cb36d4
signed: 2026-04-13T04:43:26.651Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf